Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Tolvaptan (TLV) in Korean patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH)

Next Previous
Trial Profile

Safety and Efficacy of Tolvaptan (TLV) in Korean patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Hyponatraemia
  • Focus Therapeutic Use

Most Recent Events

  • 12 Apr 2018 New trial record
  • 09 Apr 2018 Primary endpoint (The average serum sodium concentrations on days 18) has not been met, according to results published in the Journal of Korean Medical Science.
  • 09 Apr 2018 Primary endpoint (The average serum sodium concentrations on days 0 and 4) has been met, according to results published in the Journal of Korean Medical Science.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top